Pfizer588.

Methods	DESIGN Description: Randomised placebo‐controlled, double‐blind, parallel, flexible dose trial BLINDING Participants: Unclear Assessors: Unclear Administrators: Unclear ALLOCATION CONCEALMENT Method: Unclear RANDOMISATION Method: Unclear
Participants	SAMPLE Description: 193 DSM‐III‐R PTSD, physical/sexual assault, 74.6% female, average age: 37 years, average duration of illness: 10.5 years, baseline severity on CPS‐2: < 50 (except for one participant) SCREENING Primary diagnosis: Unclear Comorbidity: Unclear
Interventions	Description: sertraline (mean completer dose: 156 mg/d) versus placebo x mean of 74 days
Outcomes	CAPS‐2, CGI‐I, IES, DTS, CGI‐S (no distinction made between primary and secondary outcomes) Data estimation: Unclear
Notes	INDUSTRY SUPPORT Industry funded: Medication provided by industry: Any of the authors work for industry: ADDITIONAL INFORMATION Drop‐out rates: 50 (25.9%) dropped out in total Quality rating score: Not calculated
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)	Unclear risk	B ‐ Unclear